Could 130/80 mm hg be adopted as the diagnostic threshold and management goal of hypertension in consideration of the characteristics of asian populations?

Kazuomi Kario; Ji Guang Wang

doi:10.1161/HYPERTENSIONAHA.118.11203

Could 130/80 mm hg be adopted as the diagnostic threshold and management goal of hypertension in consideration of the characteristics of asian populations?

Kazuomi Kario
, Ji Guang Wang

Research output: Contribution to journal › Review article › peer-review

70 Scopus citations

Original language	English
Pages (from-to)	979-984
Number of pages	6
Journal	Hypertension
Volume	71
Issue number	6
DOIs	https://doi.org/10.1161/HYPERTENSIONAHA.118.11203
State	Published - 2018
Externally published	Yes

Access to Document

10.1161/HYPERTENSIONAHA.118.11203

Cite this

@article{1e5ddb99da5144dd98c5a65f83b05c0e,

title = "Could 130/80 mm hg be adopted as the diagnostic threshold and management goal of hypertension in consideration of the characteristics of asian populations?",

author = "Kazuomi Kario and Wang, \{Ji Guang\}",

note = "Funding Information: K. Kario received research funding from Teijin Pharma, Ltd, Omron Healthcare Co, Ltd, Fukuda Denshi, Bayer Yakuhin, Ltd, A\&D Co, Ltd, Daiichi Sankyo Company, Ltd, Pfizer Inc, Mochida Pharmaceutical Co, Ltd, EA Pharma, Boehringer Ingelheim Japan Inc, Tanabe Mitsubishi Pharma Corporation, Shionogi \& Co, Ltd, MSD K.K., Sanwa Kagaku Kenkyusho Co, Ltd, Bristol-Myers Squibb K.K., and honoraria from Takeda Pharmaceutical Co, Ltd and Omron Healthcare Co, Ltd. J.-G. Wang received research funding from Astra-Zeneca, Bayer, MSD, OMRON, Pfizer, and Philips and honoraria from Astra-Zeneca, Bayer, Daiichi-Sankyo, MSD, Pfizer, Sanofi, Servier, and Takeda.",

year = "2018",

doi = "10.1161/HYPERTENSIONAHA.118.11203",

language = "English",

volume = "71",

pages = "979--984",

journal = "Hypertension",

issn = "0194-911X",